Hydroxysafflor yellow A attenuates the blood-brain barrier dysfunction and neuroinflammation through anti-inflammatory microglial polarization after intracerebral hemorrhage

IF 4.6 2区 医学 Q1 NEUROSCIENCES
Fei Zheng , Xiaohang Guo , Qiuju Yan , Yaya Zhou , En Hu , Haonan Zhu , Menghan Cheng , Zhe Yu , Mingrui Hu , Ruoqi Ding , Haigang Li , Wei Zhang , Tao Tang , Yang Wang , Teng Li , Changqing Deng
{"title":"Hydroxysafflor yellow A attenuates the blood-brain barrier dysfunction and neuroinflammation through anti-inflammatory microglial polarization after intracerebral hemorrhage","authors":"Fei Zheng ,&nbsp;Xiaohang Guo ,&nbsp;Qiuju Yan ,&nbsp;Yaya Zhou ,&nbsp;En Hu ,&nbsp;Haonan Zhu ,&nbsp;Menghan Cheng ,&nbsp;Zhe Yu ,&nbsp;Mingrui Hu ,&nbsp;Ruoqi Ding ,&nbsp;Haigang Li ,&nbsp;Wei Zhang ,&nbsp;Tao Tang ,&nbsp;Yang Wang ,&nbsp;Teng Li ,&nbsp;Changqing Deng","doi":"10.1016/j.neuropharm.2025.110576","DOIUrl":null,"url":null,"abstract":"<div><div>The destruction of the blood-brain barrier (BBB) is the most common life-threatening event of intracerebral hemorrhage (ICH). Balancing microglia polarization is a prospective therapeutic strategy for BBB injury. This study aims to explore the neuroprotective effects and the underlying mechanisms of Hydroxysafflor yellow A (HSYA) from the perspective of BBB disruption and neuroinflammation. ICH was induced by intracerebral injection of collagenase Ⅶ in C57BL/6J male mice, and HSYA was injected through the tail vein for three days. We established three oral concentrations for HSYA and found that the administration of HSYA (20 mg/kg/d) significantly improved the neurological deficits of ICH mice and reversed the histopathological damage of the brain. Using IgG and Evans Blue staining, we demonstrated that HSYA prominently facilitated the BBB repair after ICH with no bleeding risk. HSYA greatly enhanced the expression of tight junction proteins (ZO-1, occludin, and claudin-5) but decreased MMP9. HSYA also significantly reduced the CD68<sup>+</sup> microglia with pro-inflammation mediators (IL-1β, IL-6, TNF-α, iNOS, HO-1, and COX2) and increased the Arg-1<sup>+</sup> microglia with anti-inflammation mediators (IL-10, and TGF-β). We identified the PI3K/Akt signaling pathway through database mining and bioinformatics analysis and verified the activation of PI3K/Akt by HSYA intervention. Further, employing the PI3K-specific antagonist LY294002 confirmed that the pre-administration of LY294002 mostly negated the neuroprotective effects of HSYA. HSYA activates the PI3K/Akt/mTOR signaling pathway, balancing microglial polarization and improving BBB integrity, highlighting its potential to be an effective drug option for ICH treatment.</div></div>","PeriodicalId":19139,"journal":{"name":"Neuropharmacology","volume":"278 ","pages":"Article 110576"},"PeriodicalIF":4.6000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0028390825002825","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

The destruction of the blood-brain barrier (BBB) is the most common life-threatening event of intracerebral hemorrhage (ICH). Balancing microglia polarization is a prospective therapeutic strategy for BBB injury. This study aims to explore the neuroprotective effects and the underlying mechanisms of Hydroxysafflor yellow A (HSYA) from the perspective of BBB disruption and neuroinflammation. ICH was induced by intracerebral injection of collagenase Ⅶ in C57BL/6J male mice, and HSYA was injected through the tail vein for three days. We established three oral concentrations for HSYA and found that the administration of HSYA (20 mg/kg/d) significantly improved the neurological deficits of ICH mice and reversed the histopathological damage of the brain. Using IgG and Evans Blue staining, we demonstrated that HSYA prominently facilitated the BBB repair after ICH with no bleeding risk. HSYA greatly enhanced the expression of tight junction proteins (ZO-1, occludin, and claudin-5) but decreased MMP9. HSYA also significantly reduced the CD68+ microglia with pro-inflammation mediators (IL-1β, IL-6, TNF-α, iNOS, HO-1, and COX2) and increased the Arg-1+ microglia with anti-inflammation mediators (IL-10, and TGF-β). We identified the PI3K/Akt signaling pathway through database mining and bioinformatics analysis and verified the activation of PI3K/Akt by HSYA intervention. Further, employing the PI3K-specific antagonist LY294002 confirmed that the pre-administration of LY294002 mostly negated the neuroprotective effects of HSYA. HSYA activates the PI3K/Akt/mTOR signaling pathway, balancing microglial polarization and improving BBB integrity, highlighting its potential to be an effective drug option for ICH treatment.
羟基红花黄A通过抗炎小胶质细胞极化减轻脑出血后血脑屏障功能障碍和神经炎症
血脑屏障(BBB)的破坏是脑出血(ICH)最常见的危及生命的事件。平衡小胶质细胞极化是治疗血脑屏障损伤的一种前瞻性治疗策略。本研究旨在从血脑屏障破坏和神经炎症的角度探讨羟基afflor yellow A (HSYA)的神经保护作用及其机制。C57BL/6J雄性小鼠脑内注射胶原酶Ⅶ诱导脑出血,尾静脉注射HSYA 3 d。我们建立了三种口服HSYA浓度,发现HSYA (20 mg/kg/d)可显著改善脑出血小鼠的神经功能缺损,逆转脑组织病理学损伤。通过IgG和Evans Blue染色,我们发现HSYA显著促进脑出血后血脑屏障修复,无出血风险。HSYA显著提高了紧密连接蛋白(ZO-1、occludin和claudin-5)的表达,但降低了MMP9的表达。HSYA还能显著降低具有促炎介质(IL-1β、IL-6、TNF-α、iNOS、HO-1和COX2)的CD68+小胶质细胞,并增加具有抗炎介质(IL-10和TGF-β)的Arg-1+小胶质细胞。我们通过数据库挖掘和生物信息学分析确定了PI3K/Akt信号通路,并验证了HSYA干预对PI3K/Akt的激活作用。此外,采用pi3k特异性拮抗剂LY294002证实,预先给药LY294002主要否定HSYA的神经保护作用。HSYA激活PI3K/Akt/mTOR信号通路,平衡小胶质细胞极化,改善血脑屏障完整性,突出了其作为脑出血治疗有效药物的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Neuropharmacology
Neuropharmacology 医学-神经科学
CiteScore
10.00
自引率
4.30%
发文量
288
审稿时长
45 days
期刊介绍: Neuropharmacology publishes high quality, original research and review articles within the discipline of neuroscience, especially articles with a neuropharmacological component. However, papers within any area of neuroscience will be considered. The journal does not usually accept clinical research, although preclinical neuropharmacological studies in humans may be considered. The journal only considers submissions in which the chemical structures and compositions of experimental agents are readily available in the literature or disclosed by the authors in the submitted manuscript. Only in exceptional circumstances will natural products be considered, and then only if the preparation is well defined by scientific means. Neuropharmacology publishes articles of any length (original research and reviews).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信